ERBB2 and breast carcinoma: Beyond HER2‐positive breast cancer, a deep learning algorithm demonstrated clinical potential in TNBC through evaluating neoadjuvant therapy (NAT) response in 165 cases, achieving an AUC of 0.62 [50].